- Open Access
Overexpression of RBM5 induces autophagy in human lung adenocarcinoma cells
- Zhenzhong Su†1,
- Ke Wang†1,
- Ranwei Li4,
- Jinzhi Yin1,
- Yuqiu Hao1,
- Xuejiao Lv1,
- Junyao Li1,
- Lijing Zhao2,
- Yanwei Du2,
- Ping Li3 and
- Jie Zhang1Email author
© Su et al. 2016
Received: 29 October 2015
Accepted: 17 February 2016
Published: 29 February 2016
Dysfunctions in autophagy and apoptosis are closely interacted and play an important role in cancer development. RNA binding motif 5 (RBM5) is a tumor suppressor gene, which inhibits tumor cells’ growth and enhances chemosensitivity through inducing apoptosis in our previous studies. In this study, we investigated the relationship between RBM5 overexpression and autophagy in human lung adenocarcinoma cells.
Human lung adenocarcinoma cancer (A549) cells were cultured in vitro and were transiently transfected with a RBM5 expressing plasmid (GV287-RBM5) or plasmid with scrambled control sequence. RBM5 expression was determined by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) and Western blot. Intracellular LC-3 I/II, Beclin-1, lysosome associated membrane protein-1 (LAMP1), Bcl-2, and NF-κB/p65 protein levels were detected by Western blot. Chemical staining with monodansylcadaverine (MDC) and acridine orange (AO) was applied to detect acidic vesicular organelles (AVOs). The ultrastructure changes were observed under transmission electron microscope (TEM). Then, transplanted tumor models of A549 cells on BALB/c nude mice were established and treated with the recombinant plasmids carried by attenuated Salmonella to induce RBM5 overexpression in tumor tissues. RBM5, LC-3, LAMP1, and Beclin1 expression was determined by immunohistochemistry staining in plasmids-treated A549 xenografts.
Our study demonstrated that overexpression of RBM5 caused an increase in the autophagy-related proteins including LC3-I, LC3-II, LC3-II/LC3-I ratio, Beclin1, and LAMP1 in A549 cells. A large number of autophagosomes with double-membrane structure and AVOs were detected in the cytoplasm of A549 cells transfected with GV287-RBM5 at 24 h. We observed that the protein level of NF-κB/P65 was increased and the protein level of Bcl-2 decreased by RBM5 overexpression. Furthermore, treatment with an autophagy inhibitor, 3-MA, enhanced RBM5-induced cell death and chemosensitivity in A549 cells. Furthermore, we successfully established the lung adenocarcinoma animal model using A549 cells. Overexpression of RBM5 enhanced the LC-3, LAMP1, and Beclin1 expression in the A549 xenografts.
Our findings showed for the first time that RBM5 overexpression induced autophagy in human lung adenocarcinoma cells, which might be driven by upregulation of Beclin1, NF-κB/P65, and downregulation of Bcl-2. RBM5-enhanced autophagy acts in a cytoprotective way and inhibition of autophagy may improve the anti-tumor efficacy of RBM5 in lung cancer.
Lung cancer is the leading cause of cancer-related mortality in the world . Nearly 85 % of these are non-small cell lung cancer (NSCLC), which typically has a poor prognosis with the overall 5-year survival rate of ~17 % despite innovations in diagnostic testing, surgical technique, and development of new chemotherapeutic agents [1, 2]. Thus, studies on new therapeutic strategies or targets are of great interest. Several of these studies are designed to target RBM5, since deregulation of RBM5 and its downstream targets have been linked to tumorigenesis and tumor maintenance in a variety of cancers, including lung cancer, breast cancer, pancreatic cancer, prostate cancer, and vestibular schwannoma [3–8].
RNA binding motif 5 (RBM5) (also called Luca15 or H37), the tumor suppressor gene, maps to the human chromosomal locus 3p21.3, which is strongly associated with lung cancer . It has been shown to function as a regulator of apoptosis and cell cycle arrest in several malignancies, particularly in NSCLC cells through pre-messenger RNA (mRNA) splicing of multiple target genes [10–12]. The ectopic expression of RBM5 suppresses the growth of human lung cancer , breast cancer , fibrosarcoma , and hematopoietic cells [15–17]. Our previous study demonstrated that exogenous expression of RBM5 by the pcDNA3.1-RBM5 inhibited the cell growth of human prostate cancer and lung cancer in vivo and in vitro and resensitized the response of A549/DDP cells (cisplatin resistant counterparts of A549 cells) to cisplatin [8, 18–20]. Although the mechanisms of RBM5-mediated tumor suppression remain not quite clear, recent studies suggest that RBM5 is involved in the regulation of the mitochondrial apoptotic pathway and Bcl-2 family expression [8, 18, 19]. It has been confirmed that Bcl-2 family also function as autophagy regulators via their interaction with the core autophagy factor Beclin family which plays an important role in the initiation of autophagosome formation [21–24]. However, the relationship between RBM5 and autophagy in human lung cancer is still unknown.
Autophagy is an evolutionarily conserved process in all eukaryotic cells, which is used for recycling cytoplasm to generate macromolecular building blocks and energy under stress conditions, to remove superfluous and damaged proteins and organelles to adapt to changing nutrient conditions and to maintain cellular homeostasis [25, 26]. Autophagy has been recognized as having a complex impact on the initiation, progression, and treatment of lung cancer . Low expression of Beclin1 was significantly associated with tumorigenesis, tumor progression, and poor prognosis in NSCLC . Inactivation of the essential autophagy gene Atg5 causes an acceleration of the early phases of NSCLC oncogenesis . Suppression of basal autophagy leads to inhibition of NSCLC cell proliferation and sensitizes them to cisplatin-induced caspase-dependent and caspase-independent apoptosis . The initiation and execution of autophagy is regulated by a number of intracellular molecules, such as autophagy-related (Atg) proteins, mTORC1, AMPK, Beclin1, Bcl-2, and PI3K/AKT pathway . Although the understanding of the regulation of autophagy has substantially advanced, information on the regulation of this complex process is limited.
In this study, we investigated the relationship of RBM5 overexpression and its potential role of autophagy modulation, which will help us to learn more about the mechanism of potential activity of RBM5 and autophagy regulation in NSCLC. Our data showed for the first time that RBM5 overexpression induced autophagy, which might be regulated by the alteration of NF-κB/P65 and Bcl-2 expression.
Cell lines and expression vectors
The human lung adenocarcinoma cell line A549 cells were obtained from the Chinese Academy of Medical Sciences. A549 cells were cultured in RPMI-1640 medium (Gibco, USA), supplemented with 10 % fetal bovine serum (Gibco, USA), 100 U/mL penicillin, and 100 μg/mL streptomycin (Sigma-Aldrich, St. Louis, USA) at 37 °C and 5 % CO2 with high humidity.
Expression vectors and reagents
RBM5 expression plasmid (NM_005778) (GV287-RBM5) and the plasmid with scrambled control sequence (GV287) were constructed by Genechem Company (Genechem, China). Cisplatin were purchased from Sigma Chemical Co. (Sigma Chemical Co., St. Louis, USA).
Transient transfections and treatments
A549 cells were transiently transfected with recombined plasmid with RBM5 gene (GV287-RBM5) or plasmid with scrambled control sequence using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s instruction as described previously [19, 20, 31], with 4 μg DNA for 9 × 105 A549 cells in a six-well plate. Five hours after the transfection, the cell culture medium was replaced with 10 % fetal bovine serum. For the pharmacological modulation of autophagy, cells were treated with 3-MA (5 mM), which is a class III phosphatidylinositol 3-kinase (PtdIns3K) inhibitor and can block the early steps of autophagy  at the same time. Twenty-four hours after transfection, the cells were stained, or harvested, or treated with cisplatin for another 24 h for MTT assays.
Cell viability assays
Cell viability was determined using 3-(4,5-dimethylthia-zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Cells were seeded at 2 × 104 cells in 100 μl per well in 96-well plates for 12 h. Then, cells were treated with different concentrations of cisplatin for 24 h. The cells were treated with 0.5 mg/ml MTT solution and incubated for 4 h at 37 °C in the dark. The supernatant was aspirated, and formazan crystals were dissolved in 100 μl of DMSO at 37 °C for 15 min with gentle agitation. The absorbance value at a wavelength of 570 nm was measured with a microplate reader (Bio-Rad, Richmond, CA). Cell viability was calculated as a percentage of the control (untreated) values. All experiments were carried out in triplicate.
Acridine orange staining
Acridine orange (AO) (Sigma Chemical Co., St. Louis, USA) was used to evaluate the formation of acid vesicular organelles (AVOs) by fluorescence microscopy. AO is a fluorescent molecule used to identify either apoptotic cell death or autophagy. It can interact with DNA emitting green fluorescence or accumulate in acidic organelles in which it becomes protonated forming aggregates that emit bright red fluorescence. After transfected with plasmids for 24 h, cells were treated with AO (1 μg/ml) in a serum-free medium and incubated for 15 min at 37 °C in the dark. Then, cells were washed four times with PBS, and fluorescent micrographs were obtained using an inverted fluorescence microscope (Olympus, Japan).
MDC incorporation assay
Another fluorescent compound, monodansylcadaverine (MDC) has been proposed as a tracer for autophagic vacuoles. Autophagic vacuoles were also detected with MDC staining. After transfected with plasmids for 24 h, cells were incubated with MDC (50 μM) (Sigma Chemical Co., St. Louis, USA) in a serum-free medium at 37 °C for 30 min in the dark. After incubation, cells were washed four times with cold PBS, and fluorescent micrographs were obtained using an inverted fluorescence microscope (Olympus, Japan).
Transmission electron microscopy
Treated cells were washed and fixed in 2.5 % glutaraldehyde for 2 h at 4 °C and then treated with 1 % osmium tetroxide, dehydrated in a graded series of ethanol baths, infiltrated and embedded in Epon resin. Ultrathin sections of 70 nM were cut in a Leica microtome (Leica, Deerfield, III), poststained with uranyl acetate and lead citrate, and examined in a HITACHI H-7650 transmission electron microscope (TEM) (HITACHI, Ltd, Japan) at an accelerating voltage of 80 kV.
Protein extraction and Western blot
Total protein from cultured cells was extracted according to the previous study . Briefly, protein concentration was measured by the Protein Assay Kit (Bio-Rad, CA). Equal amounts of protein samples (20–50 μg) were separated by 12 % SDS-PAGE and transferred onto poly (vinyl idene fluoride) (PVDF) membranes (Millipore, USA). The membranes were treated with Tris-buffered saline and Tween-20 solution (TBST) containing 50 g/L skim milk at room temperature for 1 h, and incubated overnight at 4 °C with an antibody against RBM5 (Santa Cruz Biotechnology, CA), LC3A/B (Proteintech Group, USA), Beclin1 (Proteintech Group, USA), Bcl-2 (Proteintech Group, USA), NF-κB/p65 (Affinity, USA), or LAMP1 (Abcam, USA). The mouse monoclonal antibody against β-actin (Proteintech Group, USA) was used as a housekeeping control gene. Membranes were washed three times for 10 min with TBST and incubated with horseradish peroxidase-conjugated secondary antibodies (Proteintech Group, USA) at a dilution of 1:500 for 1 h at room temperature. Membranes were washed three times for 10 min with TBST, and bands were then detected using an Enhanced Chemiluminescence (ECL) Detection kit (Pierce Biotechnology Ltd., Rockford, IL, USA) and quantified by densitometry using Quantity One software (Bio-Rad).
RNA extraction and semi-quantitative RT-PCR
Reverse transcription-polymerase chain reaction (RT-PCR) was performed essentially as described previously . In brief, total RNA was extracted from the cells using a Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. The ratio of absorbance at 260 and 280 nm (A260/280) was measured to assess RNA purity and quantity. First-strand complementary DNA (cDNA) was generated using All-in-One™ First-Strand cDNA Synthesis Kit (GeneCopoeia, Inc, USA) according to the manufacturer’s instructions. Primers were made by Sangon Biotech (Sangon Biotech, China). The primer sequences were as follows: GAPDH sense: 5′-CATGTAGTTGAGGTCAATGAAGG-3′ and antisense: 5′-GAGCCACATCGCTCAGACAC-3′; RBM5 sense: 5′-GCACGACTATAGGCATGACAT-3′ and antisense: 5′-AGTCAAACTTGTCTGCTCCA-3′. PCR was performed at 95 °C for 5 min and 28–30 cycles of 95 °C for 30 s, 58 °C for 30 s, 72 °C for 45 s, and 72 °C for 10 min. The PCR products were separated by electrophoresis on 1 % agarose gels containing ethidium bromide. The PCR products were visualized by a Tanon-1600 figure gel image processing system and analyzed with a GIS 1D gel image system software (Tanon, Shanghai, China).
Establishment of A549 xenografts
The use of animal was in accordance with animal care guidelines, and the protocol was approved by Jilin University Animal Care Committee. A549 xenografts were established, and RBM5 gene was delivered into xenografts by attenuated Salmonella according to previous studies [18, 31]. Briefly, BALB/c athymic nude female mice (nu/nu; 4–5 weeks old) were purchased from the Institute of Zoology, Chinese Academy of Sciences (Beijing, China). A549 cells (1 × 107) were suspended in 100 μl PBS and injected subcutaneously into the right flank region of nude mice.
Competent Salmonella enterica serovar Typhimurium cells (competence) were mixed with 1 μg GV287-RBM5 or 1 μg control plasmids and cooled for 15 min on ice. And the plasmids were electrotransfected into the competence under the conditions as follows: C = 25 μF, PC = 200 Ω, V = 1.25 kV (12.5 kV/cm). Then, the recombinant attenuated salmonellae were quickly transferred into LB Ager medium for proliferation at 37 °C and stored at −80 °C.
The tumor-bearing mice were randomly divided into two groups (six mice per group) at day 21 after cell injection. The mice were treated at day 28 and 35 respectively through a tail mainline as follows: (a) control group (attenuated Salmonella carrying control plasmids) (108 colony-forming units (CFU) per 50μlPBS); (b) RBM5 overexpression group (attenuated salmonella carrying GV287-RBM5 plasmids) (108 CFU per 50 μl PBS). The mice were sacrificed on day 42, and the tumors were removed and fixed in formalin for immunohistochemistry analysis.
Tumors treated with recombinant Salmonella strains carrying different plasmids were analyzed by immunohistochemistry staining as described previously . Anti-human mouse RBM5 antibody was obtained from Santa Cruz Biotechnology (Santa Cruz Biotechnology, USA). Anti-human rabbit LC-3 antibody was obtained from Proteintech Group (Proteintech Group, USA). Anti-human rabbit LAMP1 antibody was obtained from Abcam (Abcam, USA). Anti-human rabbit Beclin1 antibody was obtained from Proteintech Group (Proteintech Group, USA).
All data were presented as mean ± standard deviation (SD) for three independent experiments. Student’s t test was used to compare the difference between two groups (two-tailed; P < 0.05 was considered statistically significant). The analysis was performed using SPSS 17.0 software.
Ectopic expression of RBM5 enhanced autophagic vacuoles formation in A549 cells
We previously reported that RBM5 overexpression induced apoptosis in human lung adenocarcinoma A549 cells [19, 20]. However, the relationship between RBM5 overexpression and autophagy, which is closely related to apoptosis, has not been elucidated. To investigate whether ectopic expression of RBM5 modulates autophagy machinery in A549 cells, A549 cells were transiently transfected with RBM5 expressing plasmid (GV287-RBM5) (RBM5 group) or negative control plasmid (control group).
AO and MDC are fluorescent substances, which are specific markers for autophagic vacuoles and are often used to detect the occurrence of autophagy . In AO stained cells, cytoplasm and nucleolus showed green fluorescence whereas AVOs showed bright red fluorescence. Intensity of red fluorescence is proportional to the number of AVOs in autophagic cells. With AO staining, we observed that red fluorescent spots were increased in RBM5 overexpressed A549 cells compared to the control cells (Fig. 1e), indicating that RBM5 overexpression enhanced autophagic vacuoles formation. When cells were co-treated with RBM5 transfection and a classic autophagy inhibitor 3-MA (5 mM), the increment of acridine orange-positive AVOs was inhibited and there were more nucleus presenting yellow-green fluorescence by acridine orange (AO) staining and concentrating into a crescent or granules that located in one side of the cells compared to RBM5 group (Fig. 1e), suggesting that 3-MA inhibited RBM5 induced autophagy and enhanced RBM5 induced early-stage apoptosis. MDC accumulates in mature autophagic vacuoles, such as autophagolysosomes, but not in the early endosome compartment . In MDC stained cells, AVOs appear as distinct dot-like structures distributed within the cytoplasm or localizing in the perinuclear regions. With MDC staining, we observed that the RBM5 overexpressed A549 cells showed a greater fluorescence intensity and a greater number of MDC-labeled particles in the cytoplasm of the cells compared to the control group (Fig. 1f), indicating that overexpression of RBM5 increased MDC recruitment to autophagosomes which was suppressed by the autophagy inhibitor, 3-MA (Fig. 1f).
Additionally, ultrastructural changes in treated cells were examined with TEM. TEM images in control group displayed normal cytoplasm and were characterized by mitochondria, endoplasmic reticulum, free ribosomes, and irregular nucleus, as well as few autophagosomes and lysosomes (Fig. 1g). In contrast, RBM5 group exhibited many autophagosomes at various stages in cytoplasm. Arrows indicated typical double-membrane-bound vacuoles containing morphologically intact cytoplasm, organelles, or electron-dense contents (Fig. 1g). The co-treated A549 cells exhibited less autophagosomes than RBM5 group but showed the following findings: peripheral chromatin condensation, undulations in the boundaries of the nucleus, lipid droplets, glycogen accumulation, mitochondrial injury, degeneration and dilatation of the endoplasmic reticulum, increased lysosomes, and intracytoplasmic vacuolization (Fig. 1g), indicating that 3-MA inhibited RBM5-induced autophagy but enhanced RBM5-induced apoptosis.
Overexpression of RBM5 induced cell autophagy-related protein expression
LAMP1 is a structural protein on the membranes of late endosomes and lysosomes and is well-known for its regulation of lysosomal motility and membrane fusion events between autophagosomes with late endosomes/lysosomes . We observed that LAMP1 expression was increased significantly in RBM5 overexpressed A549 cells compared to that in the control group (Fig. 2a, b; P < 0.001), indicating an upregulation of lysosomal activity and the fusion of autophagosomes with lysosomes in the RBM5 overexpressed cells. However, 3-MA inhibited LAMP1 expression significantly in co-treatment group compared to the RBM5 group (Fig. 2a, b; P < 0.001).
Overall, these data indicated that RBM5 overexpression could induce autophagic flux in human lung cancer A549 cells, and this process could be suppressed by the autophagy inhibitor, 3-MA.
In order to investigate the mechanism that RBM5 induced autophagy, we evaluated the expression levels of autophagy regulators, Beclin1, NF-κB/p65, and Bcl-2 by Western blot analysis. Beclin1 plays an important role in initiating the formation of autophagosomes, NF-κB/p65 is an inducer of autophagy through the activation of Beclin1 , and Bcl-2 is an inhibitor of Beclin1-dependent autophagy . The results showed that the expression levels of Beclin1, as well as NF-κB/p65, were increased significantly (P < 0.001) in RBM5 overexpression group, which were inhibited by co-treatment of RBM5 and 3-MA (Fig. 2d, e). On the contrary, the expression level of Bcl-2 was decreased significantly in RBM5 overexpression group compared to the control group (Fig. 2d, e; P < 0.001) and can be reversed by 3-MA in the co-treatment group (Fig. 2d, e; P < 0.01). These data suggested that overexpression of RBM5 could induce autophagy through the upregulation of Beclin1, which might consequently switch on the downstream reaction via the activation of NF-κB/p65,inactivation of Bcl-2, and invoke the autophagy process.
Pharmacological modulation of autophagy enhanced overexpressed RBM5-induced apoptosis and chemosensitivity
Our previous studies showed that RBM5 inhibited the growth of A549 cells and resensitized A549/DDP cells to cisplatin through apoptosis [8, 18–20]. In the present study, we found that inhibition of autophagy, which was induced by the co-treatment of overexpressed RBM5 and 3-MA, enhanced RBM5 induced A549 cell growth inhibition and sensitivity to cisplatin. The data above suggested that autophagy activated by RBM5 overexpression functions as a pro-survival factor and prevents cell death triggered by RBM5. And autophagy inhibition by 3-MA could enhance RBM5-induced apoptosis and chemosensitivity.
RBM5 overexpression induced autophagy in A549 xenografts in BALB/c nude mice
Previous studies demonstrated that RBM5 displayed effective antiproliferative activity in cell lines derived from human solid tumors, such as lung cancer and prostate cancer, including multidrug resistant cells [8, 18–20]. RBM5 is known as a tumor suppressor gene that has been shown to function on cell growth inhibition by inducing apoptosis. Autophagy and apoptosis are closely related programmed cell activities, which are of great importance to determine cell death and/or survival. Autophagy is emerging as a key process modulating tumorigenesis, tumor-stroma interactions and cancer therapy, but plays a dual, context-dependent role in tumor suppression and survival . Autophagy plays a protective role in cancer cells in certain circumstances ; however, in other circumstances it is involved in type II programmed cell death [39, 40]. From a therapeutic perspective, understanding when and how autophagy can be harnessed to kill cancer cells remains challenging . Therefore, a better understanding about regulation relationship of RBM5 on autophagy and the role autophagy plays in cell survival is critical for developing therapeutic strategies targeting RBM5 in lung cancer and understanding more about mechanisms of autophagy regulation.
In the present study, we experimentally conducted overexpression of RBM5 in human lung adenocarcinoma A549 cells and for the first time demonstrated that autophagy, aside from apoptosis alone, was also activated by RBM5 overexpression. The increased autophagic flux in the RBM5 overexpressed A549 cells was demonstrated by the enhancement of LC3-II, LC3-II/LC3-I, and Beclin1 together with the accumulation of AVOs assessed by AO staining, MDC staining and TEM, and the upregulation of lysosomal activity and autophagolysosomal fusion characterized by increased levels of LAMP1. In order to confirm our in vitro results, the lung adenocarcinoma transplantation in vivo model was made by injecting A549 cells onto the back of immunocompromised mice and RBM5 gene was delivered into xenografts by attenuated Salmonella. As shown in the results, increased autophagic flux in the RBM5 overexpressed A549 xenografts was confirmed by the overexpression of LC3, Beclin1, and LAMP1 evaluated by immunohistochemistry staining.
Autophagy induction in mammalian cells is mainly dependent upon the activation of the class III PI3K or PI3K/AKT/mTOR pathways . Beclin1 (Atg6) is a well-known key regulator of autophagy , which governs the autophagic process by regulating class III PI3K pathway activated autophagosome formation [44, 45]. Increased Beclin1 expression was also observed in the RBM5 overexpressed A549 cells and A549 xenografts in the present study. However, when Beclin1-PI3K III complex was inhibited by 3-MA, Beclin1 expression was downregulated and autophagic flux was decreased, confirming a crucial role for Beclin1 in RBM5-induced autophagy in lung cancer cells.
Bcl-2, an anti-apoptotic protein, is also a Beclin1 binding protein and act as an autophagy regulator [22–24]. As demonstrated in previous studies [18, 19], we found that RBM5 overexpression decreased the level of bcl-2 protein that occurred, along with the induction of autophagy in A549 cells in the present study, indicating that downregulation of Bcl-2 was also involved in RBM5-induced autophagy. Interestingly, we also found that administration of 3-MA prevented RBM5-induced downregulation of Bcl-2. Likewise, results were reported by Xie H et al. that Beclin1 proteins was decreased but Bcl-2 was upregulated in 3-MA-treated H9c2 rat cardiomyocytes , which might be due to strong interaction between Beclin1 and Bcl-2.
NF-κB/p65 is another regulator of Beclin1-mediated autophagy [36, 47], which could be inhibited by 3-MA . Our results again showed that overexpression of RBM5 activated Beclin1-mediated autophagy mainly through activation of NF-κB/p65 pathway and inhibition of Bcl-2. NF-κB/p65 protein levels, along with cell autophagy were overexpressed by RBM5 overexpression, which was inhibited by 3-MA in A549 cells, indicating that NF-κB/p65 was regulated by RBM5 and was involved in RBM5-induced autophagy.
However, the mechanisms that RBM5 regulates Beclin-1, Bcl-2, and NF-κB/p65 still need to be investigated. It is reported that RBM5 is a component of prespliceosomal complexes that regulates the alternative splicing of several mRNAs, such as Fas and caspase-2 [49, 50]. As overexpression of Beclin1 and NF-κB/p65 and downregulation of Bcl-2 can be inhibited by 3-MA, RBM5 may directly or indirectly regulate those genes expression through regulating such genes expression of class III PI3K pathway, like Beclin1 or other genes, by alternative splicing of mRNAs.
Besides those genes examined in this study, our previous studies revealed that RBM5 also regulates such genes expression as Bcl-2 family [18, 19], EGFR [4, 31], and β-catenin , which are all important autophagy regulators [23, 24, 52–55]. Thus, it is a complicated process of autophagy regulation by RBM5 that needs to be further investigated.
The role of autophagy in carcinogenesis is a paradox, which can be a pro-survival mechanism to deteriorate therapeutic outcomes or act as programmed cell death to improve overall anti-tumor efficacy . In order to investigate the role of activated autophagy plays in RBM5-induced cell death, the present study used a specific autophagy inhibitor, 3-MA, which is a class III phosphatidylinositol 3-kinase (PI3K) inhibitor. RBM5 overexpression induced autophagy in A549 cells was significantly inhibited by the administration of 3-MA. Furthermore, the inhibition of autophagy enhanced RBM5-induced cell death and increased cancer cell sensitivity to cisplatin in A549 cells, maybe through enhanced apoptosis. These findings indicate that autophagy may be utilized as a protective mechanism against cell death in RBM5 overexpressed A549 cells and that its inhibition may improve the anti-tumor efficacy of RBM5 in lung cancer therapies.
Apoptosis is a natural way of removing aged cells from the body and is the way by which most of the anti-cancer therapies eliminate malignant cells. However, several pathways modulate the apoptosis signaling and contribute to apoptosis resistance in cancers, such as Bcl-2 and Mcl-1 proteins, autophagy processes, aberrant nuclear export signaling, etc . Autophagy has been observed to protect cancer cells from apoptosis upon certain anti-cancer drugs [58, 59] and gene targeting therapies [60, 61]. Our previous studies demonstrated that RBM5 can inhibit the growth of lung cancer cells and enhance cancer cells’ sensitivity to cisplatin through apoptosis [8, 18–20]. In the present study, we found that autophagy induced by RBM5 overexpression in lung cancer cells acted a pro-survival way. However, actually RBM5 overexpression caused cell growth inhibition, indicating that in the lung cancer cells, RBM5-induced apoptosis overweighs RBM5-induced autophagy and induces apoptotic cell death. Co-treatment with 3-MA inhibited RBM5-induced autophagy, enhanced RBM5-induced apoptosis and chemosensitivity. Thus, modulating the sensitivity and regulatory mechanism of cells to RBM5 overexpression, such as through the use of 3-MA, could potentially serve as a strategy in sensitizing and reducing resistance of lung cancer cells to RBM5 targeting therapy by blocking RBM5-mediated protective autophagy.
Overall, our data revealed that the pro-survival autophagy is enhanced by ectopic RBM5 overexpression, and inhibition of autophagy can enhance RBM5-induced apoptosis and increase cancer cells sensitivity to cisplatin. Our study suggests that a combination of RBM5 overexpression and autophagic inhibitor could be a good approach to treat NSCLC and resensitize cells to anti-tumor drugs.
This study was supported by the grant from the National Natural Science Foundation of China (NO. 81071919), Norman Bethune Program of Jilin University (NO. 2012220), Provincial Training Program of Science and Technology for Innovative Talents of Jilin (No. 20130521002JH), and the Natural Science Foundation of Jilin Province (No.20150101151JC) for KW. This study was supported by the grant from the National Natural Science Foundation of China (NO. 81472169) for JZ.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi:10.3322/caac.21208.View ArticlePubMedGoogle Scholar
- DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71. doi:10.3322/caac.21235.View ArticlePubMedGoogle Scholar
- Peng J, Valeshabad AK, Li Q, Wang Y. Differential expression of RBM5 and KRAS in pancreatic ductal adenocarcinoma and their association with clinicopathological features. Oncol Lett. 2013;5(3):1000–4. doi:10.3892/ol.2012.1080.PubMed CentralPubMedGoogle Scholar
- Liang H, Zhang J, Shao C, Zhao L, Xu W, Sutherland LC, et al. Differential expression of RBM5. EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues. J Exp Clin Cancer Res. 2012;31:36. doi:10.1186/1756-9966-31-36.PubMed CentralView ArticlePubMedGoogle Scholar
- Rintala-Maki ND, Goard CA, Langdon CE, Wall VE, Traulsen KE, Morin CD, et al. Expression of RBM5-related factors in primary breast tissue. J Cell Biochem. 2007;100(6):1440–58. doi:10.1002/jcb.21134.View ArticlePubMedGoogle Scholar
- Oh JJ, West AR, Fishbein MC, Slamon DJ. A candidate tumor suppressor gene, H37, from the human lung cancer tumor suppressor locus 3p21.3. Cancer Res. 2002;62(11):3207–13.PubMedGoogle Scholar
- Welling DB, Lasak JM, Akhmametyeva E, Ghaheri B, Chang LS. cDNA microarray analysis of vestibular schwannomas. Otol Neurotol. 2002;23(5):736–48.View ArticlePubMedGoogle Scholar
- Zhao L, Li R, Shao C, Li P, Liu J, Wang K. 3p21.3 tumor suppressor gene RBM5 inhibits growth of human prostate cancer PC-3 cells through apoptosis. World J Surg Oncol. 2012;10:247. doi:10.1186/1477-7819-10-247.PubMed CentralView ArticlePubMedGoogle Scholar
- Timmer T, Terpstra P, van den Berg A, Veldhuis PM, Ter Elst A, van der Veen AY, et al. An evolutionary rearrangement of the Xp11.3-11.23 region in 3p21.3, a region frequently deleted in a variety of cancers. Genomics. 1999;60(2):238–40. doi:10.1006/geno.1999.5878.View ArticlePubMedGoogle Scholar
- Sutherland LC, Wang K, Robinson AG. RBM5 as a putative tumor suppressor gene for lung cancer. J Thorac Oncol. 2010;5(3):294–8. doi:10.1097/JTO.0b013e3181c6e330.View ArticlePubMedGoogle Scholar
- Oh JJ, Razfar A, Delgado I, Reed RA, Malkina A, Boctor B, et al. 3p21.3 tumor suppressor gene H37/Luca15/RBM5 inhibits growth of human lung cancer cells through cell cycle arrest and apoptosis. Cancer Res. 2006;66(7):3419–27. doi:10.1158/0008-5472.CAN-05-1667.View ArticlePubMedGoogle Scholar
- Maarabouni MM, Williams GT. The antiapoptotic RBM5/LUCA-15/H37 gene and its role in apoptosis and human cancer: research update. Sci World J. 2006;6:1705–12. doi:10.1100/tsw.2006.268.View ArticleGoogle Scholar
- Rintala-Maki ND, Abrasonis V, Burd M, Sutherland LC. Genetic instability of RBM5/LUCA-15/H37 in MCF-7 breast carcinoma sublines may affect susceptibility to apoptosis. Cell Biochem Funct. 2004;22(5):307–13. doi:10.1002/cbf.1106.View ArticlePubMedGoogle Scholar
- Edamatsu H, Kaziro Y, Itoh H. LUCA15, a putative tumour suppressor gene encoding an RNA-binding nuclear protein, is down-regulated in ras-transformed Rat-1 cells. Genes Cells. 2000;5(10):849–58.View ArticlePubMedGoogle Scholar
- Mourtada-Maarabouni M, Sutherland LC, Meredith JM, Williams GT. Simultaneous acceleration of the cell cycle and suppression of apoptosis by splice variant delta-6 of the candidate tumour suppressor LUCA-15/RBM5. Genes Cells. 2003;8(2):109–19.View ArticlePubMedGoogle Scholar
- Rintala-Maki ND, Sutherland LC. LUCA-15/RBM5, a putative tumour suppressor, enhances multiple receptor-initiated death signals. Apoptosis. 2004;9(4):475–84. doi:10.1023/B:APPT.0000031455.79352.57.View ArticlePubMedGoogle Scholar
- Sutherland LC, Edwards SE, Cable HC, Poirier GG, Miller BA, Cooper CS, et al. LUCA-15-encoded sequence variants regulate CD95-mediated apoptosis. Oncogene. 2000;19(33):3774–81. doi:10.1038/sj.onc.1203720.View ArticlePubMedGoogle Scholar
- Shao C, Yang B, Zhao L, Wang S, Zhang J, Wang K. Tumor suppressor gene RBM5 delivered by attenuated Salmonella inhibits lung adenocarcinoma through diverse apoptotic signaling pathways. World J Surg Oncol. 2013;11:123. doi:10.1186/1477-7819-11-123.PubMed CentralView ArticlePubMedGoogle Scholar
- Shao C, Zhao L, Wang K, Xu W, Zhang J, Yang B. The tumor suppressor gene RBM5 inhibits lung adenocarcinoma cell growth and induces apoptosis. World J Surg Oncol. 2012;10:160. doi:10.1186/1477-7819-10-160.PubMed CentralView ArticlePubMedGoogle Scholar
- Li P, Wang K, Zhang J, Zhao L, Liang H, Shao C, et al. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin. Cancer Epidemiol. 2012;36(5):481–9. doi:10.1016/j.canep.2012.04.004.View ArticlePubMedGoogle Scholar
- He C, Wei Y, Sun K, Li B, Dong X, Zou Z, et al. Beclin 2 functions in autophagy, degradation of G protein-coupled receptors, and metabolism. Cell. 2013;154(5):1085–99. doi:10.1016/j.cell.2013.07.035.PubMed CentralView ArticlePubMedGoogle Scholar
- Erlich S, Mizrachy L, Segev O, Lindenboim L, Zmira O, Adi-Harel S, et al. Differential interactions between Beclin 1 and Bcl-2 family members. Autophagy. 2007;3(6):561–8.View ArticlePubMedGoogle Scholar
- Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S, Thompson CB, et al. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol. 2004;6(12):1221–8. doi:10.1038/ncb1192.View ArticlePubMedGoogle Scholar
- Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005;122(6):927–39. doi:10.1016/j.cell.2005.07.002.View ArticlePubMedGoogle Scholar
- Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell. 2004;6(4):463–77.View ArticlePubMedGoogle Scholar
- Feng Y, He D, Yao Z, Klionsky DJ. The machinery of macroautophagy. Cell Res. 2014;24(1):24–41. doi:10.1038/cr.2013.168.PubMed CentralView ArticlePubMedGoogle Scholar
- Ryter SW, Choi AM. Autophagy in lung disease pathogenesis and therapeutics. Redox Biol. 2015;4:215–25. doi:10.1016/j.redox.2014.12.010.View ArticlePubMedGoogle Scholar
- Zhou W, Yue C, Deng J, Hu R, Xu J, Feng L, et al. Autophagic protein Beclin 1 serves as an independent positive prognostic biomarker for non-small cell lung cancer. PLoS ONE. 2013;8(11), e80338. doi:10.1371/journal.pone.0080338.PubMed CentralView ArticlePubMedGoogle Scholar
- Rao S, Yang H, Penninger JM, Kroemer G. Autophagy in non-small cell lung carcinogenesis: a positive regulator of antitumor immunosurveillance. Autophagy. 2014;10(3):529–31. doi:10.4161/auto.27643.PubMed CentralView ArticlePubMedGoogle Scholar
- Kaminskyy VO, Piskunova T, Zborovskaya IB, Tchevkina EM, Zhivotovsky B. Suppression of basal autophagy reduces lung cancer cell proliferation and enhances caspase-dependent and -independent apoptosis by stimulating ROS formation. Autophagy. 2012;8(7):1032–44. doi:10.4161/auto.20123.PubMed CentralView ArticlePubMedGoogle Scholar
- Su Z, Yin J, Zhao L, Li R, Liang H, Zhang J, et al. Lentiviral vector-mediated RBM5 over-expression downregulates EGFR expression in human non-small cell lung cancer cells. World J Surg Oncol. 2014;12:367. doi:10.1186/1477-7819-12-367.PubMed CentralView ArticlePubMedGoogle Scholar
- Klionsky DJ. Coming soon to a journal near you—the updated guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2014;10(10):1691.PubMed CentralView ArticlePubMedGoogle Scholar
- Luo T, Liu G, Ma H, Lu B, Xu H, Wang Y, et al. Inhibition of autophagy via activation of PI3K/Akt pathway contributes to the protection of ginsenoside Rb1 against neuronal death caused by ischemic insults. Int J Mol Sci. 2014;15(9):15426–42. doi:10.3390/ijms150915426.PubMed CentralView ArticlePubMedGoogle Scholar
- Munafo DB, Colombo MI. A novel assay to study autophagy: regulation of autophagosome vacuole size by amino acid deprivation. J Cell Sci. 2001;114(Pt 20):3619–29.PubMedGoogle Scholar
- Saftig P, Schroder B, Blanz J. Lysosomal membrane proteins: life between acid and neutral conditions. Biochem Soc Trans. 2010;38(6):1420–3. doi:10.1042/BST0381420.View ArticlePubMedGoogle Scholar
- Zeng M, Wei X, Wu Z, Li W, Li B, Zhen Y, et al. NF-kappaB-mediated induction of autophagy in cardiac ischemia/reperfusion injury. Biochem Biophys Res Commun. 2013;436(2):180–5. doi:10.1016/j.bbrc.2013.05.070.View ArticlePubMedGoogle Scholar
- Weckman A, Rotondo F, Di Ieva A, Syro LV, Butz H, Cusimano MD, et al. Autophagy in endocrine tumors. Endocr Relat Cancer. 2015;22(4):R205–18. doi:10.1530/ERC-15-0042.View ArticlePubMedGoogle Scholar
- Rabinowitz JD, White E. Autophagy and metabolism. Science. 2010;330(6009):1344–8. doi:10.1126/science.1193497.PubMed CentralView ArticlePubMedGoogle Scholar
- Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 1999;402(6762):672–6. doi:10.1038/45257.View ArticlePubMedGoogle Scholar
- Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci USA. 2003;100(25):15077–82. doi:10.1073/pnas.2436255100.PubMed CentralView ArticlePubMedGoogle Scholar
- Maes H, Rubio N, Garg AD, Agostinis P. Autophagy: shaping the tumor microenvironment and therapeutic response. Trends Mol Med. 2013;19(7):428–46. doi:10.1016/j.molmed.2013.04.005.View ArticlePubMedGoogle Scholar
- Yang Z, Klionsky DJ. Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol. 2010;22(2):124–31. doi:10.1016/j.ceb.2009.11.014.PubMed CentralView ArticlePubMedGoogle Scholar
- He R, Peng J, Yuan P, Xu F, Wei W. Divergent roles of BECN1 in LC3 lipidation and autophagosomal function. Autophagy. 2015;11(5):740–7. doi:10.1080/15548627.2015.1034404.PubMed CentralView ArticlePubMedGoogle Scholar
- Wirawan E, Lippens S, Vanden Berghe T, Romagnoli A, Fimia GM, Piacentini M, et al. Beclin1: a role in membrane dynamics and beyond. Autophagy. 2012;8(1):6–17. doi:10.4161/auto.8.1.16645.View ArticlePubMedGoogle Scholar
- Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011;18(4):571–80. doi:10.1038/cdd.2010.191.PubMed CentralView ArticlePubMedGoogle Scholar
- Xie H, Liu Q, Qiao S, Jiang X, Wang C. Delayed cardioprotection by sevoflurane preconditioning: a novel mechanism via inhibiting Beclin 1-mediated autophagic cell death in cardiac myocytes exposed to hypoxia/reoxygenation injury. Int J Clin Exp Pathol. 2015;8(1):217–26.PubMed CentralPubMedGoogle Scholar
- Shulak L, Beljanski V, Chiang C, Dutta SM, Van Grevenynghe J, Belgnaoui SM, et al. Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-kappaB-dependent autophagy. J Virol. 2014;88(5):2927–40. doi:10.1128/JVI.03406-13.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang T, Wang H, Li Q, Huang J, Sun X. Modulating autophagy affects neuroamyloidogenesis in an in vitro ischemic stroke model. Neuroscience. 2014;263:130–7. doi:10.1016/j.neuroscience.2014.01.012.View ArticlePubMedGoogle Scholar
- Fushimi K, Ray P, Kar A, Wang L, Sutherland LC, Wu JY. Up-regulation of the proapoptotic caspase 2 splicing isoform by a candidate tumor suppressor, RBM5. Proc Natl Acad Sci U S A. 2008;105(41):15708–13. doi:10.1073/pnas.0805569105.PubMed CentralView ArticlePubMedGoogle Scholar
- Bonnal S, Martinez C, Forch P, Bachi A, Wilm M, Valcarcel J. RBM5/Luca-15/H37 regulates Fas alternative splice site pairing after exon definition. Mol Cell. 2008;32(1):81–95. doi:10.1016/j.molcel.2008.08.008.View ArticlePubMedGoogle Scholar
- Hao YQ, Su ZZ, Lv XJ, Li P, Gao P, Wang C, et al. RNA-binding motif protein 5 negatively regulates the activity of Wnt/beta-catenin signaling in cigarette smoke-induced alveolar epithelial injury. Oncol Rep. 2015;33(5):2438–44. doi:10.3892/or.2015.3828.PubMedGoogle Scholar
- Tan X, Thapa N, Sun Y, Anderson RA. A kinase-independent role for EGF receptor in autophagy initiation. Cell. 2015;160(1-2):145–60. doi:10.1016/j.cell.2014.12.006.PubMed CentralView ArticlePubMedGoogle Scholar
- Wei Y, Zou Z, Becker N, Anderson M, Sumpter R, Xiao G, et al. EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell. 2013;154(6):1269–84. doi:10.1016/j.cell.2013.08.015.PubMed CentralView ArticlePubMedGoogle Scholar
- Lin R, Feng J, Dong S, Pan R, Zhuang H, Ding Z. Regulation of autophagy of prostate cancer cells by beta-catenin signaling. Cell Physiol Biochem. 2015;35(3):926–32. doi:10.1159/000369749.View ArticlePubMedGoogle Scholar
- Chang HW, Lee YS, Nam HY, Han MW, Kim HJ, Moon SY, et al. Knockdown of beta-catenin controls both apoptotic and autophagic cell death through LKB1/AMPK signaling in head and neck squamous cell carcinoma cell lines. Cell Signal. 2013;25(4):839–47. doi:10.1016/j.cellsig.2012.12.020.View ArticlePubMedGoogle Scholar
- Wu WK, Coffelt SB, Cho CH, Wang XJ, Lee CW, Chan FK, et al. The autophagic paradox in cancer therapy. Oncogene. 2012;31(8):939–53. doi:10.1038/onc.2011.295.View ArticlePubMedGoogle Scholar
- Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, et al. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol. 2015. doi:10.1016/j.semcancer.2015.03.001.Google Scholar
- Xi G, Hu X, Wu B, Jiang H, Young CY, Pang Y, et al. Autophagy inhibition promotes paclitaxel-induced apoptosis in cancer cells. Cancer Lett. 2011;307(2):141–8. doi:10.1016/j.canlet.2011.03.026.View ArticlePubMedGoogle Scholar
- Liu D, Yang Y, Liu Q, Wang J. Inhibition of autophagy by 3-MA potentiates cisplatin-induced apoptosis in esophageal squamous cell carcinoma cells. Med Oncol. 2011;28(1):105–11. doi:10.1007/s12032-009-9397-3.View ArticlePubMedGoogle Scholar
- Yuan G, Yan SF, Xue H, Zhang P, Sun JT, Li G. Cucurbitacin I induces protective autophagy in glioblastoma in vitro and in vivo. J Biol Chem. 2014;289(15):10607–19. doi:10.1074/jbc.M113.528760.PubMed CentralView ArticlePubMedGoogle Scholar
- Mani J, Vallo S, Rakel S, Antonietti P, Gessler F, Blaheta R, et al. Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (-)-Gossypol (AT-101). BMC Cancer. 2015;15:224. doi:10.1186/s12885-015-1239-4.PubMed CentralView ArticlePubMedGoogle Scholar